CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in treatments for primary and metastatic cancers of the brain and central nervous system, announced that the company’s GMP manufacturer partner NCK A/S, received a Certificate of Analysis (CoA) for its Active Pharma Ingredient (API), clearing it for use in the production of Berubicin. As previously announced, CNS signed a contract with NCK A/S for the large-scale production of Berubicin, its lead drug candidate for the...